Some new perspectives for the correction of lipid risk factor of atherosclerosis
Dyslipidemia is one of the leading risk factors for atherosclerosis-associated cardiovascular disease, along with hypertension and smoking. Not only non-drug measures have great importance in the correction of this risk factor, but also cholesterol-lowering medicines. Now the statins are recognized...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Siberian Branch of Russian Academy of Sciences, Research Institute of Internal and Preventive Medicine, branch of the Institute of Cytology and Genetics
2013-06-01
|
| Series: | Атеросклероз |
| Subjects: | |
| Online Access: | https://ateroskleroz.elpub.ru/jour/article/view/677/615 |
| Summary: | Dyslipidemia is one of the leading risk factors for atherosclerosis-associated cardiovascular disease, along with hypertension and smoking. Not only non-drug measures have great importance in the correction of this risk factor, but also cholesterol-lowering medicines. Now the statins are recognized as the most effective and safe. However, its effect of the maximum dose is insufficient or accompanied by side effects in some patients. Currently, several new classes of drugs have tested in clinical trials: cholesterol ester transfer protein inhibitors, blockers of apoprotein B synthesis, analogue of thyroid hormones; immunological intervention ways are developed, by monoclonal antibodies in particular. |
|---|---|
| ISSN: | 2078-256X |